Related Experiment Video

Updated: May 27, 2026

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Role and expression of FRS2 and FRS3 in prostate cancer

Tania Valencia1, Ajay Joseph, Naveen Kachroo

  • 1Translational Prostate Cancer Group, Department of Oncology, Hutchison/MRC research centre, University of Cambridge, Cambridge, UK.

BMC Cancer
|November 15, 2011
PubMed
Abstract

Insights

Targeting both FGF receptor substrates 2 and 3 (FRS2 and FRS3) disrupts prostate cancer cell growth and survival. Dual inhibition selectively harms malignant cells, offering a potential new therapeutic strategy.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • FGF receptor substrates (FRS2 and FRS3) are crucial adaptor proteins in FGF-FGFR signaling pathways.
  • These pathways are implicated in both normal tissue function and the development of various cancers.
  • Understanding their role in prostate cancer is key to developing targeted therapies.

Purpose of the Study:

  • To investigate the roles of FRS2 and FRS3 in prostate cancer.
  • To explore the potential of disrupting FGF signaling by targeting FRS2 and FRS3.
  • To assess the therapeutic efficacy of dual FRS2 and FRS3 inhibition in prostate cancer models.

Main Methods:

  • In vitro manipulation of FRS2 and FRS3 using overexpression and knockdown techniques.
  • Functional assays to assess cell proliferation, migration, and invasion.
  • Expression profiling of FRS2 and FRS3 in prostate cancer cell lines and clinical tumor samples.

Main Results:

  • FRS2 and FRS3 are ubiquitously expressed in benign and malignant prostate cells.
  • Dual suppression of FRS2 and FRS3 significantly inhibited ERK activation, proliferation, migration, and invasion.
  • Combined FRS2/FRS3 knockdown with irradiation synergistically reduced prostate cancer cell survival without affecting benign cells.

Conclusions:

  • FRS2 and FRS3 exhibit functional redundancy in mediating mitogenic FGF signaling in prostate cancer.
  • While not overexpressed in tumors, FRS2 and FRS3 are viable therapeutic targets.
  • Targeted dual inhibition of FRS2 and FRS3 shows selective efficacy against malignant prostate cells.

More Related Videos

miRNA Expression Analyses in Prostate Cancer Clinical Tissues11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)08:30

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR (qPCR)

Published on: May 16, 2012

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...